Dr. Michael Taylor, Ph.D., DABT, is the Founder
and Principal at NonClinical Safety Assessment, a
consulting firm focusing on the safety evaluation of
drugs and medical devices. With more than 20 years of
R&D experience in the biopharmaceutical industry he has
supported development across a wide variety of
therapeutic areas. Dr. Taylorís experience includes both
small and large molecules and multiple modes of drug
delivery (CNS, ocular, dermal, SC, PO, IV), including
pumps, patches, and controlled release formulations.
Prior to establishing NonClinical Safety Assessment Dr.
Taylor held positions of increasing responsibility in
both large and small biopharmaceutical companies. He is
a member of both the Society of Toxicology and the
American College of Toxicology, certified by the
American Board of Toxicology, holds Ph.D. and M.S.
degrees in toxicology from Utah State University, gained
postdoctoral training from the NIH and CNRS (France), and is an active member of the Stanford
University Medical School SPARK advisory board providing
guidance to aspiring biomedical entrepreneurs.